课题基金 / 基金详情

Prognostic and Therapeutic Utility of Human Antigen R (HuR) in Fibrosis

Prognostic and Therapeutic Utility of Human Antigen R (HuR) in Fibrosis
人类抗原 R (HuR) 在纤维化中的预后和治疗效用
批准号:
407811
负责人:
Baglole Carolyn
金额:
$60.75万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2019
资助国家:
加拿大
项目状态:
已结题
起止时间:
2019-09-01 至 2024-09-01

项目摘要

项目成果

Baglole Carolyn的其他基金

相似基金

相关文献

中文摘要
翻译
肺纤维化发生时,肺变得疤痕和僵硬,导致呼吸衰竭死亡。肺纤维化患者的平均生存期只有3-5年,比许多类型的癌症更差。原因之一是
英文摘要
Pulmonary fibrosis occurs when the lung becomes scarred and stiffened, leading to death from respiratory failure. The average survival of an individual with pulmonary fibrosis is only 3-5 years, worse than many types of cancer. One of the reasons is that
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Decoding how the aryl hydrocarbon receptor (AhR) controls cigarette smoke-induced lung inflammation and development of chronic obstructive pulmonary disease (COPD)
Immunological consequences of inhaled cannabis and selected cannabinoids
Molecular regulation of cigarette smoke-induced pulmonary disease by the aryl hydrocarbon receptor
海外基金